LG Life Sciences has invested and researched constantly over the past two decades to secure core competencies in the diagnostics area. This effort has enabled the company to develop in vitro diagnostics for hepatitis C (first in Korea), malaria antibodies (first in the world), HIV antigens and antibodies, syphilis and hepatitis B virus.
LG Life Sciences researchers have worked with other topnotch scientists inside and outside Korea to classify diseases according the human genes and to find trace substances necessary for early diagnostics of disease. In a bid to find next-generation diagnostic methodologies, the company is developing seminal technology and products related to protein chips, which can be used to find multiple disease markers simultaneously.
LG Life Sciences will continue its concerted effort to emerge as a top global brand in the diagnostics field.